| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2015 | A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results. | Yang, James Chih-Hsin; Srimuninnimit, Vichien; Ahn, Myung-Ju; Lin, Chia-Chi; Kim, Sang-We; Tsai, Chun-Ming; Mok, Tony; Orlando, Mauro; Puri, Tarun; Wang, Xin; Park, Keunchil | J. Clin. Oncol. | | | |
| 2015 | Antitumor Activity of Tepotinib plus Gefitinib in Asian Patients with Met plus EGFRm plus NSCLC | Kim, Dong-Wan; Soo, Ross; Yang, James Chih-Hsin; Park, Keunchil; Stammberger, Uz; Xiong, Huiiling; Ihling, Christian; Wu, Yi-Long; Wu, Yi-Long | J. Thorac. Oncol. | | | |
| 2015 | AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases. | Kim, Dong-Wan; Yang, James Chih-Hsin; Chen, Kan; Cheng, Ziqiang; Yin, Lucy; Martin, Paul David; Yang, Zhenfan; Jiang, Haiyi; Ahn, Myung-Ju | J. Clin. Oncol. | | | |
| 2015 | AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort. | Ramalingam, Suresh S.; Yang, James Chih-Hsin; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Rukazenkov, Yuri; Frewer, Paul; Cantarini, Mireille; Ghiorghiu, Serban; Janne, Pasi A. | J. Clin. Oncol. | | | |
| 2014 | Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non-Small-Cell Lung Cancer | Lee, Jih-Hsiang; Lin, Yu-Lin; Hsu, Wei-Hsun; Chen, Hsuan-Yu; Chang, Yeun-Chung; Yu, Chong-Jen; Shih, Jin-Yuan; Lin, Chia-Chi; Chen, Kuan-Yu; Ho, Chao-Chi; Laio, Wei-Yu; Yang, Pan-Chyr; Yang, James Chih-Hsin | J. Thorac. Oncol. | | | |
| 2014 | Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non-Small-Cell Lung Cancer | Lee, Jih-Hsiang; Lin, Yu-Lin; Hsu, Wei-Hsun; Chen, Hsuan-Yu; Chang, Yeun-Chung; Yu, Chong-Jen; Shih, Jin-Yuan; Lin, Chia-Chi; Chen, Kuan-Yu; Ho, Chao-Chi; Laio, Wei-Yu; Yang, Pan-Chyr; Yang, James Chih-Hsin; 楊泮池 | J. Thorac. Oncol. | | | |
| 2013 | Diarrhea associated with afatinib: an oral ErbB family blocker | Yang, James Chih-Hsin; Reguart, Noemi; Barinoff, Jana; Koehler, Jens; Uttenreuther-Fischer, Martina; Stammberger, Uz; O'Brien, Dennis; Wolf, Juergen; Cohen, Ezra E. W. | Expert Review of Anticancer Therapy | 68 | 82 | |
| 2013 | EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer | Kao, Hsiang-Fong; Lin, Chia-Chi; Yang, James Chih-Hsin | Future Oncology | 7 | 6 | |
| 2015 | Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis. | Liao, Bin-Chi; Lee, Jih-hsiang; Lin, Chia-Chi; Ho, Chao-Chi; Shih, Jin-Yuan; Yu, Chong-Jen; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
| 2015 | Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis. | Liao, Bin-Chi; Lee, Jih-hsiang; Lin, Chia-Chi; Ho, Chao-Chi; Shih, Jin-Yuan; Yu, Chong-Jen; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
| 2015 | First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. | Tan, Daniel Shao-Weng; Tan, Daniel Shao-Weng; Seto, Takashi; Seto, Takashi; Leighl, Natasha B.; Riely, Gregory J.; Riely, Gregory J.; Sequist, Lecia V.; Felip, Enriqueta; Wolf, Juergen; Yang, James Chih-Hsin; Matushansky, Igor; Matushansky, Igor; Yu, Xiaolu; Yu, Xiaolu; Schmitz, Shu-Fang Hsu; Cui, Xiaoming; Kim, Dong-Wan | J. Clin. Oncol. | | | |
| 2015 | How to use afatinib in clinical practice | Yang, James Chih-Hsin | Ann. Oncol. | | | |
| 2015 | Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC). | Yang, James Chih-Hsin; Yang, James Chih-Hsin; Ahn, Myung-Ju; Dickgreber, Nicolas J.; Halmos, Balazs; Hirsh, Vera; Hochmair, Maximilian J.; Hochmair, Maximilian J.; Levy, Benjamin Philip; De Marinis, Filippo; De Marinis, Filippo; Mok, Tony; Mok, Tony; O'Byrne, Kenneth; O'Byrne, Kenneth; Okamoto, Isamu; Schuler, Martin H.; Sebastian, Martin; Sebastian, Martin; Shah, Riyaz N. H.; Shah, Riyaz N. H.; Tan, Eng-Huat; Tan, Eng-Huat; Yamamoto, Nobuyuki; Yamamoto, Nobuyuki; Marten, Angela; Massey, Dan; Massey, Dan; Wind, Sven; Wind, Sven; Carbone, David Paul | J. Clin. Oncol. | | | |
| 2015 | Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial). | Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Hsia, Te-Chun; Chen, Chen-Hsin; Chang, Gee-Chen; Shih, Jin-Yuan; Ho, Ching-Liang; Chen, Yuh-Min; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
| 2015 | Maintenance with Gefitinib/Pemetrexed (G/P) or P After Induction P/Platinum for Stage IV Lung Adenocarcinoma with No Sensitizing EGFR Mutation | Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Hsia, Te-Chun; Chen, Chen-Hsin; Chang, Gee-Chen; Shih, Jin-Yuan; Ho, Ching-Liang; Chen, Yuh-Min; Yang, James Chih-Hsin | J. Thorac. Oncol. | | | |
| 2013 | Neoadjuvant Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2 Non-Small-Cell Lung Cancer | Liao, Wei-Yu; Chen, Jin-Hsin; Wu, Muzo; Shih, Jin-Yuan; Chen, Kuan-Yuh; Ho, Chao-Chi; Yang, James Chih-Hsin; Yu, Chong-Jen | Clin. Lung Cancer | | |  |
| 2015 | Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. | Papadimitrakopoulou, Vassiliki; Patnaik, Amita; Borghaei, Hossein; Stevenson, James; Gandhi, Leena; Gubens, Matthew A.; Yang, James Chih-Hsin; Sequist, Lecia V.; Ge, Joy Yang; Bourque, Jennifer; Bachman, Robert D.; Im, Ellie; Gadgeel, Shirish M. | J. Clin. Oncol. | | | |
| 2015 | Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. | Oxnard, Geoffrey R.; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Yu, Helena Alexandra; Saka, Hideo; Horn, Leora; Goto, Koichi; Ohe, Yuichiro; Cantarini, Mireille; Frewer, Paul; Lahn, Michael; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
| 2014 | The impact of diabetes mellitus on early cervical cancer in Asia: A population-based cohort study | Kuo, Hung-Yang; Lin, Zhong-Zhe; Kuo, Raymond Nienchen; Shau, Wen-Yi; Lai, Chiu-Lin; Yang, Yen-Yun; Shao, Yu Yun; Hsu, Chiun; Chang, Wen-Fang; Chang, Ann-Lii; Yang, James Chih-Hsin; Lai, Mei-Shu; 鄭安理 | J. Clin. Oncol. | | | |
| 2015 | The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials. | Lee, Chee; Davies, Lucy Claire; Wu, Yi-Long; Mitsudomi, Tetsuya; Inoue, Akira; Rosell, Rafael; Zhou, Caicun; Nakagawa, Kazuhiko; Throngprasert, Sumitra; Fukuoka, Masahiro; Gralla, Richard J.; Gebski, Val; Mok, Tony; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
